G, M., N, I., K, R., J, G., E, S., F, R., . . . C, L. T. (2021). Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Investigational new drugs, 39(6), 1641. https://doi.org/10.1007/s10637-021-01152-z
Chicago Style (17th ed.) CitationG, Marret, et al. "Phase I Trial of Copanlisib, a Selective PI3K Inhibitor, in Combination with Cetuximab in Patients with Recurrent And/or Metastatic Head and Neck Squamous Cell Carcinoma." Investigational New Drugs 39, no. 6 (2021): 1641. https://doi.org/10.1007/s10637-021-01152-z.
MLA (9th ed.) CitationG, Marret, et al. "Phase I Trial of Copanlisib, a Selective PI3K Inhibitor, in Combination with Cetuximab in Patients with Recurrent And/or Metastatic Head and Neck Squamous Cell Carcinoma." Investigational New Drugs, vol. 39, no. 6, 2021, p. 1641, https://doi.org/10.1007/s10637-021-01152-z.
